BEAM THERAPEUTICS INC.

Beam Therapeutics Announces FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for BEAM-201

02 Dec 2022 06:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Participate in the BofA Securities 2022 Virtual Biotech SMID Cap Conference

30 Nov 2022 06:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics Enrolls First Patient in BEACON Clinical Trial of BEAM-101 Base Editing Therapy Candidate for the Treatment of Sickle Cell Disease

14 Nov 2022 06:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Participate in Upcoming Investor Conferences

09 Nov 2022 06:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics Announces Portfolio Progress and Reports Third Quarter 2022 Financial Results

07 Nov 2022 06:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Present New Preclinical Data Highlighting Non-Genotoxic Conditioning Regimens for Patients with Sickle Cell Disease Ahead of Autologous Transplant at the 64th ASH Annual Meeting

03 Nov 2022 09:01:00 By Nasdaq GlobeNewswire

Beam Therapeutics Presents First In Vivo Data Demonstrating Potential of Multiplex Base Editing Approach to Target Disease Drivers of Chronic Hepatitis B Infection

19 Sep 2022 06:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Participate at the Wells Fargo 2022 Healthcare Conference

01 Sep 2022 06:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics Announces Pipeline and Business Highlights and Reports Second Quarter 2022 Financial Results

09 Aug 2022 06:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference

02 Aug 2022 08:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Present First Research Highlighting Approach to Develop Non-Genotoxic Conditioning Regimens for Patients with Sickle Cell Disease Ahead of Autologous Transplant

27 Jun 2022 06:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Participate in the 2022 Jefferies Healthcare Conference

03 Jun 2022 06:42:39 By Nasdaq GlobeNewswire

Beam Therapeutics Announces Pipeline and Business Highlights and Reports First Quarter 2022 Financial Results

09 May 2022 06:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Participate in Upcoming May Investor Conferences

04 May 2022 06:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease Conference

25 Mar 2022 06:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Participate in the Barclays 2022 Global Healthcare Conference

08 Mar 2022 06:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics Reports Pipeline and Business Highlights, Planned 2022 Milestones and Fourth Quarter and Full Year 2021 Financial Results

28 Feb 2022 06:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Present at the SVB Leerink 11th Annual Global Healthcare Conference

09 Feb 2022 06:30:00 By Nasdaq GlobeNewswire

Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases

10 Jan 2022 06:00:00 By Nasdaq GlobeNewswire

Beam Therapeutics Reports Progress Across Ex Vivo and In Vivo Pipeline of Base Editing Therapeutics and Outlines Key Anticipated 2022 Milestones

09 Jan 2022 09:00:00 By Nasdaq GlobeNewswire